Biogen Idec (BIIB)

$226.63 0.23 (0.10%)

16:00 EDT BIIB Stock Quote Delayed 30 Minutes

Biogen Inc: Regenerate Profits in a Bear-Trapped BIIB

By Chris Tyler, InvestorPlace Contributor Mar 11, 2016

A failure to go up on good news and continuously move down on worrisome reports suggest bears aren’t done in BIIB.

62 Stock Upgrades (and Downgrades) for the Week

53 Trades to Stay Ahead of the Curve

Profit From the Dip in Biotech Stocks With This IBB Options Play

Volume:

Previous Close -

Market Cap 32.63B

PE Ratio 35.97

EPS 6.3

Volume (Avg. Vol.) 692,372

Day's Range $223.62 - $228.48

52-Week Range $189.44 - $280.41

Dividend & Yield N/A (N/A)

BIIB Stock Predictions, Articles, and Biogen Idec News

71 Trades to Combat the Chill on Wall Street

By Feb 2, 2016

During busy times it pays to stay on top of the latest profit opportunities. Today's blog post is a great place to start with these stocks to buy

The 10 Best Healthcare Stocks to Buy Now

By John Divine, InvestorPlace Assistant Editor Jan 28, 2016

This list of the 10 best healthcare stocks to buy now includes extremely well-capitalized companies paying extraordinary dividends ... and trading for cheap.

Why Weight Watchers International, Inc. (WTW), Capital One Financial Corp. (COF) and Biogen Inc (BIIB) are 3 of Today’s Best Stocks

By Ethan Roberts, InvestorPlace Contributor Jan 27, 2016

Earnings and Fed language kept markets off balance today, but Weight Watchers, Capital One and Biogen had everything going their way.

Biogen Inc Looking Better After Earnings (BIIB)

By James Brumley, InvestorPlace Feature Writer Jan 27, 2016

Biogen (BIIB) was a miserable performer in the second half of 2015, but the fears weren't completely merited.

Biogen Inc. Earnings Preview: What Option Traders Are Expecting From BIIB Stock

By Chris Tyler, InvestorPlace Contributor Jan 26, 2016

With a potential bottom coming in Biogen stock, the situation looks well-suited to using a March vertical spread.

7 Battered Biotech Stocks: Bargains or Busts?

By Brian Nichols, InvestorPlace Contributor Jan 14, 2016

Biotech stocks have suffered big losses in 2016. Some are great buying opportunities, but the rest are just disasters.

Trade of the Day: BIIB Stock is Due for a Pop

By Serge Berger, InvestorPlace Contributor Dec 23, 2015

Following a healthy correction, Biogen Inc. is poised to break through resistance.

Why Biogen Stock Is Still A Sell (BIIB)

By Brian Nichols, InvestorPlace Contributor Oct 28, 2015

Biogen stock has fallen 30% the last six months, but BIIB could still go a lot lower as its MS franchise is challenged and other drugs fail to reach potential.

Biogen Stock Finally Has More Upside Than Downside

By James Brumley, InvestorPlace Feature Writer Oct 21, 2015

After a 30% beat-down just since June (and down 40% since March's peak), Biogen stock is a buy now that the company is streamlining.

BIIB Stock: What to Know Before Biogen Earnings

By James Brumley, InvestorPlace Feature Writer Oct 20, 2015

Down more than 40% since March, the fragile BIIB stock needs to deliver on its third-quarter earnings.

Biggest Movers in Healthcare Stocks Now – HZNP CLDX ARIA CLVS

By Portfolio Grader Oct 9, 2015

Healthcare stocks advanced 0.8% on Wall Street on Friday morning.

Biggest Movers in Healthcare Stocks Now – EXAS REGN AMGN CELG

By Portfolio Grader Oct 7, 2015

Healthcare stocks rose broadly on Wall Street on Wednesday morning, with the sector seeing an overall increase of 0.7%.

Be Careful Before Loving Leveraged Biotech ETFs

By Todd Shriber, InvestorPlace Contributor Oct 6, 2015

The new crop of triple-leveraged biotech ETFs have had staggering returns (and losses), serving as a reminder that not all investors should be involved with leveraged ETFs.

Biggest Movers in Healthcare Stocks Now – ISIS ALXN IPXL PBYI

By Portfolio Grader Sep 30, 2015

Healthcare stocks rose 2.1% on Wall Street on Wednesday.

Biogen: BIIB Stock May Be a Rare Biotech Value

By James Brumley, InvestorPlace Feature Writer Sep 18, 2015

Rather than dwelling on the negatives of BIIB stock, it's time to start accentuating Biogen's positives -- like promising trials and a large pipeline.